Catalyst Event
Sanofi (SNY) · Other
From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)
3/24/2026, 12:00:00 AM
Sanofi and Regeneron's Dupixent approval in Japan for bullous pemphigoid on 2026-03-24. Estimated importance based on market expansion for key drug scheduled.
Korean Translation
사노피와 리제네론의 듀피젠트 일본 승인(2026-03-24). 수포성 유사천포창 치료제 시장 확대에 따른 영향을 바탕으로 중요도를 예상함. 예정됨.
Related Recent Events
Broadcom Inc (AVGO) · Earnings Release
Q2 2026 earnings release on June 4, 2026; a Medium impact is estimated as quarterly earnings are key drivers of stock volatility, scheduled.
6/4/2026, 12:00:00 AM
Credo Technology Group Holding Ltd (CRDO) · Earnings Release
Next earnings release for Q4 fiscal 2026 on June 1, 2026, scheduled.
6/1/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA PDUFA action date for the subcutaneous formulation of LEQEMBI for treatment initiation in early Alzheimer's disease is scheduled. This regulatory milestone is estimated to have a medium impact on stock price.
5/24/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Biogen's Q1 2026 earnings release is expected around this date, based on past reporting schedules. Earnings releases typically result in moderate price volatility.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is expected to report its Q1 2026 earnings on May 7, 2026, with analysts forecasting an EPS of approximately -$0.55. Market impact is estimated at ≥1% as earnings dates are routine; scheduled.
5/7/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q1 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM